Iressa, a new oral drug for lung cancer
February 2004
Health Canada will allow the use of Iressa, a new oral drug for lung cancer...under a conditional approval.
Iressa (gefitinib) is an "epidermal growth factor inhibitor."
It will be reserved for patients whose cancer progresses despite standard chemotherapy.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote